Published in Br J Clin Pharmacol on June 01, 1999
Pain on injection with microemulsion propofol. Br J Clin Pharmacol (2008) 1.47
Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. Br J Clin Pharmacol (2002) 0.96
A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res (2012) 0.94
Preparation and anesthetic properties of propofol microemulsions in rats. Anesthesiology (2006) 0.91
The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults. Br J Clin Pharmacol (2014) 0.80
An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children. CPT Pharmacometrics Syst Pharmacol (2013) 0.76
Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ (1992) 7.20
Fatal side-effects of continuous propofol infusion in children may be related to malignant hyperthermia. Anaesth Intensive Care (1996) 2.11
Fatal metabolic acidosis in a pediatric patient receiving an infusion of propofol in the intensive care unit: is there a relationship? Crit Care Med (1995) 1.86
Propofol. An update of its use in anaesthesia and conscious sedation. Drugs (1995) 1.39
Reducing pain during propofol injection: the role of the solvent. Anesth Analg (1996) 1.38
The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part I). Clin Pharmacokinet (1989) 1.30
Pain on injection of propofol: effects of concentration and diluent. Br J Anaesth (1991) 1.30
Plasma fentanyl concentrations and clinical observations during and after operation. Br J Anaesth (1979) 1.21
Effect of speed of injection on induction of anaesthesia using propofol. Br J Anaesth (1985) 1.20
Pharmacokinetics of propofol in female patients. Studies using single bolus injections. Br J Anaesth (1987) 1.17
Disposition of propofol in patients undergoing surgery. A comparison in men and women. Br J Anaesth (1986) 1.11
Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs (1995) 1.02
Pharmacokinetics and pharmacodynamics of propofol in a new solvent. Anesth Analg (1997) 0.98
Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. Pharm Res (1998) 0.97
Determination of propofol in low-volume samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl (1998) 0.97
Extended blood collection period required to define distribution and elimination kinetics of propofol. Br J Clin Pharmacol (1988) 0.96
Pharmacology of an emulsion formulation of ICI 35 868. Br J Anaesth (1984) 0.96
Propofol emulsion for induction and maintenance of anaesthesia. A combined technique of general and regional anaesthesia. Acta Anaesthesiol Scand (1987) 0.92
Dose requirements of ICI 35,868 (propofol, 'Diprivan') in a new formulation for induction of anaesthesia. Anaesthesia (1984) 0.92
Propofol pharmacokinetics and pharmacodynamics assessed from a cremophor EL formulation. J Pharm Sci (1997) 0.91
Influence of sample site on blood concentrations of ICI 35868. Br J Anaesth (1983) 0.88
Emulsion formulation reduces propofol's dose requirements and enhances safety. Anesthesiology (1997) 0.85
Pharmacokinetics of propofol in women undergoing elective caesarean section. Br J Anaesth (1990) 0.84
Drug pharmacokinetics in the postoperative period. Clin Pharmacokinet (1979) 0.84
Pharmacokinetic evaluation of ICI 35 868 in man. Single induction doses with different rates of injection. Br J Anaesth (1983) 0.83
An adverse reaction to the administration of disoprofol (Diprivan). Anaesthesia (1982) 0.82
Arteriovenous concentration differences of propofol during and after a stepdown infusion. Anesth Analg (1994) 0.79
Effect of prolonged sedation with propofol on serum triglyceride and cholesterol concentrations. Br J Anaesth (1989) 0.79
New physiologically based methods for calculating the apparent steady-state volume of distribution in pharmacokinetic studies. Int J Clin Pharmacol Ther Toxicol (1982) 0.77
ICI 35868 (Diprivan): a new intravenous induction agent. A comparison with methohexitone. Anaesthesia (1980) 0.77
Trehalose synthesis genes are controlled by the putative sigma factor encoded by rpoS and are involved in stationary-phase thermotolerance in Escherichia coli. J Bacteriol (1991) 4.15
Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet (2001) 3.62
Inactivation of the N-CAM gene in mice results in size reduction of the olfactory bulb and deficits in spatial learning. Nature (1994) 3.19
Cotransfer of two linked human genes into cultured mouse cells. Proc Natl Acad Sci U S A (1976) 2.93
Microarray-based identification of a novel Streptococcus pneumoniae regulon controlled by an autoinduced peptide. J Bacteriol (2000) 2.85
Osmotic regulation of rpoS-dependent genes in Escherichia coli. J Bacteriol (1993) 2.83
Therapeutic drug monitoring in saliva. Clin Pharmacokinet (1978) 2.66
The RNA-binding protein HF-I plays a global regulatory role which is largely, but not exclusively, due to its role in expression of the sigmaS subunit of RNA polymerase in Escherichia coli. J Bacteriol (1997) 2.31
Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology (1979) 2.31
Informatics and medicine--from molecules to populations. Methods Inf Med (2008) 2.13
Identification and characterization of stationary phase-inducible genes in Escherichia coli. Mol Microbiol (1993) 2.05
Posttranscriptional osmotic regulation of the sigma(s) subunit of RNA polymerase in Escherichia coli. J Bacteriol (1996) 1.81
Operation for infective endocarditis: results after implantation of mechanical valves. Ann Thorac Surg (1998) 1.73
Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1996) 1.70
Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol (1984) 1.60
Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. AJNR Am J Neuroradiol (1998) 1.55
Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers. Br J Clin Pharmacol (1979) 1.55
Adjustable tricuspid valve annuloplasty assisted by intraoperative transesophageal color Doppler echocardiography. Am J Cardiol (1993) 1.50
Role of bladder neck mobility and urethral closure pressure in predicting outcome of tension-free vaginal tape (TVT) procedure. Ultrasound Obstet Gynecol (2006) 1.50
Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients. Clin Pharmacol Ther (2007) 1.47
Vascular tracheobronchial compression syndromes-- experience in surgical treatment and literature review. Thorac Cardiovasc Surg (2000) 1.47
Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth (2005) 1.44
Simulation of arterial hemodynamics after partial prosthetic replacement of the aorta. Ann Thorac Surg (1999) 1.44
Differential effects of enzyme induction on antipyrine metabolite formation. Br J Clin Pharmacol (1982) 1.43
Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. Br J Anaesth (2013) 1.42
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther (1992) 1.41
Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth (2006) 1.41
Fat distribution and cardiovascular risk factors in obese adolescent girls: importance of the intraabdominal fat depot. Am J Clin Nutr (1996) 1.41
The impact of television on attitudes towards organ donation--a survey in a German urban population sample. Nephrol Dial Transplant (1999) 1.40
Modeling and simulation at the interface of nonclinical and early clinical drug development. CPT Pharmacometrics Syst Pharmacol (2013) 1.40
Monitoring of soluble HLA class I size variants after liver transplantation. Hum Immunol (1999) 1.40
Auxiliary rat liver transplantation with portal vein arterialization in acute hepatic failure. Transplantation (2000) 1.39
Transferral of extrathoracic donor neoplasm by the cardiac allograft. J Heart Lung Transplant (1997) 1.39
Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. Xenobiotica (1979) 1.37
Interplay between global regulators of Escherichia coli: effect of RpoS, Lrp and H-NS on transcription of the gene osmC. Mol Microbiol (1998) 1.34
A model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther (2010) 1.30
Competent Bacillus subtilis cultures synthesize a denatured DNA binding activity. Proc Natl Acad Sci U S A (1975) 1.29
Central adiposity and its metabolic correlates in obese adolescent girls. Am J Physiol (1995) 1.26
PACSIN, a brain protein that is upregulated upon differentiation into neuronal cells. Eur J Biochem (1998) 1.26
Reconstruction of the RVOT with valved biological conduits: 25 years experience with allografts and xenografts. Eur J Cardiothorac Surg (2000) 1.20
Studies of experimental coronary artery reperfusion. Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage. Circulation (1983) 1.15
Myocardial blood flow and flow reserve after coronary reimplantation in patients after arterial switch and ross operation. Circulation (2001) 1.13
Evidence for a new type of outer membrane lipid in oral spirochete Treponema denticola. Functioning permeation barrier without lipopolysaccharides. J Biol Chem (1998) 1.13
Reaction of neuronal nitric-oxide synthase with oxygen at low temperature. Evidence for reductive activation of the oxy-ferrous complex by tetrahydrobiopterin. J Biol Chem (1998) 1.13
Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Brain Res Rev (1997) 1.13
Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time. Eur J Clin Pharmacol (1982) 1.13
Assessing the probability of drug-induced QTc-interval prolongation during clinical drug development. Clin Pharmacol Ther (2011) 1.12
Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. J Pharmacol Exp Ther (1998) 1.11
Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm. Clin Pharmacokinet (1997) 1.11
Single centre experience on primary correction of common arterial trunk: overall survival and freedom from reoperation after more than 15 years. Eur J Cardiothorac Surg (2000) 1.11
Does pelvic magnetic resonance imaging differentiate among the histologic subtypes of uterine leiomyomata? Fertil Steril (1998) 1.11
Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia (2004) 1.11
Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol (1988) 1.09
Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis. Arch Dermatol (1991) 1.09
[Isolated left ventricular papillary muscle rupture: a rare event after blunt thoracic trauma]. Z Kardiol (2001) 1.09
Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol (1996) 1.07
In vitro protection of amphibian gastric mucosa by nutrient HCO3- against aspirin injury. Gastroenterology (1985) 1.07
Aortopulmonary window with ventricular septal defect and pulmonary atresia: prenatal diagnosis and successful early surgical correction. Ultrasound Obstet Gynecol (2004) 1.06
Formation of a protonated trihydrobiopterin radical cation in the first reaction cycle of neuronal and endothelial nitric oxide synthase detected by electron paramagnetic resonance spectroscopy. J Biol Inorg Chem (2001) 1.06
Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford) (2005) 1.06
Studies by e.p.r. spectroscopy of carbon monoxide oxidases from Pseudomonas carboxydovorans and Pseudomonas carboxydohydrogena. Biochem J (1983) 1.05
Meniscal abnormalities in the asymptomatic population at MR imaging. Radiology (1990) 1.04
Definition of a gastric emptying abnormality in patients with anorexia nervosa. Dig Dis Sci (1985) 1.04
Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther (1994) 1.04
Further evidence for Borrelia burgdorferi infection in morphea and lichen sclerosus et atrophicus confirmed by DNA amplification. J Invest Dermatol (1993) 1.04
Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach. Br J Clin Pharmacol (1988) 1.04
Acute efficacy and chronic follow-up of patients with non-thoracotomy third generation implantable defibrillators. Pacing Clin Electrophysiol (1994) 1.03
Application of high hydrostatic pressure for increasing activity and stability of enzymes. Biotechnol Bioeng (1996) 1.03
TnTIN and TnTAP: mini-transposons for site-specific proteolysis in vivo. Proc Natl Acad Sci U S A (1997) 1.03
Clinical and serological aspects of patients with anti-Jo-1 antibodies--an evolving spectrum of disease manifestations. Clin Rheumatol (2000) 1.02
Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. Pharmacol Ther (1988) 1.02
The osmotic adjustment in the euryhaline teleosts, the flounder, Pleuronectes flesus L. and the three-spined stickleback, Gasterosteus aculeatus L. Comp Biochem Physiol (1965) 1.01
Prognostic B-cell epitopes on the flagellar protein of Borrelia burgdorferi. Infect Immun (1992) 1.01
Auxiliary liver transplantation with arterialization of the portal vein for acute hepatic failure. Transpl Int (1998) 1.00
Kinetics of drug action in disease states. II. Effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss of righting reflect. J Pharmacol Exp Ther (1984) 1.00
Time course and extent of improvement of dysfunctioning myocardium in patients with coronary artery disease and severely depressed left ventricular function after revascularization: correlation with positron emission tomographic findings. J Am Coll Cardiol (2000) 1.00
Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet (1992) 0.99
Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit (1994) 0.99
Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intensive Care Med (1997) 0.99
The fragile site (16) (q22). I. Induction by AT-specific DNA-ligands and population frequency. Hum Genet (1986) 0.99
Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes. Eur J Biochem (1991) 0.99
Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. Clin Pharmacol Ther (1985) 0.99
From trial and error to trial simulation. Part 1: the importance of model-based drug development for antidepressant drugs. Clin Pharmacol Ther (2009) 0.99
Partial agonism of theophylline-7-riboside on adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol (1994) 0.99
Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. J Pharmacol Exp Ther (1998) 0.99
Arterialization of the portal vein in orthotopic and auxiliary liver transplantation. A report of three cases. Transplantation (1995) 0.98
Pressure versus heat-induced unfolding of ribonuclease A: the case of hydrophobic interactions within a chain-folding initiation site. Biochemistry (1999) 0.98
Repair of interrupted aortic arch: results after more than 20 years. Ann Thorac Surg (2000) 0.98
Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. Eur J Pharmacol (1996) 0.98
Characterization of the pressure-induced intermediate and unfolded state of red-shifted green fluorescent protein--a static and kinetic FTIR, UV/VIS and fluorescence spectroscopy study. J Mol Biol (2003) 0.98
Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther (1987) 0.98
Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol (2004) 0.98
Hemodynamic performance and incidence of patient-prosthesis mismatch of the complete supraannular perimount magna bioprosthesis in the aortic position. Thorac Cardiovasc Surg (2005) 0.98
Determination of propofol in low-volume samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl (1998) 0.97
Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricep muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscle. J Clin Invest (1995) 0.97
Characterization of an "in vitro" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther (1988) 0.97
Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. Pharm Res (1998) 0.97